Company profile for Augustine Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Augustine Therapeutics is dedicated to advancing the discovery and development of innovative medicines for patients affected by Charcot-Marie-Tooth disease (CMT), peripheral neuropathies, and neurodegenerative disorders. The company's foundation is built upon groundbreaking research conducted at VIB (Vlaams Instituut voor Biotechnologie) and KU Leuven, bolstered by support from influential partners including Asabys Partners, E...
Augustine Therapeutics is dedicated to advancing the discovery and development of innovative medicines for patients affected by Charcot-Marie-Tooth disease (CMT), peripheral neuropathies, and neurodegenerative disorders. The company's foundation is built upon groundbreaking research conducted at VIB (Vlaams Instituut voor Biotechnologie) and KU Leuven, bolstered by support from influential partners including Asabys Partners, Eli Lilly and Company, V-Bio Ventures, PMV (Participatie Maatschappij Vlaanderen), AdBio Partners, VIB itself, the Gemma Frisius Fund, and the CMT Research Foundation

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Belgium
Address
Address
Gaston Geenslaan 1 , Leuven, Flemish Region 3001
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/05/27/3088320/0/en/Augustine-Therapeutics-announces-first-patient-dosed-in-Phase-I-clinical-trial-evaluating-lead-candidate-AGT-100216-for-the-treatment-of-Charcot-Marie-Tooth-disease.html

GLOBENEWSWIRE
27 May 2025

https://www.globenewswire.com/news-release/2025/05/27/3088478/0/en/Augustine-Therapeutics-announces-first-patient-dosed-in-Phase-I-clinical-trial-evaluating-lead-candidate-AGT-100216-for-the-treatment-of-Charcot-Marie-Tooth-disease.html

GLOBENEWSWIRE
27 May 2025

https://www.globenewswire.com/news-release/2025/05/21/3085580/0/en/Augustine-Therapeutics-appoints-Rie-Schultz-Hansen-PhD-as-Chief-Scientific-Officer-and-establishes-Copenhagen-based-subsidiary.html

GLOBENEWSWIRE
21 May 2025

https://www.globenewswire.com/news-release/2025/05/21/3085397/0/en/Augustine-Therapeutics-appoints-Rie-Schultz-Hansen-PhD-as-Chief-Scientific-Officer-and-establishes-Copenhagen-based-subsidiary.html

GLOBENEWSWIRE
21 May 2025

https://www.globenewswire.com/news-release/2025/04/30/3071170/0/en/Augustine-Therapeutics-builds-its-Management-Team-with-Virginie-Cartage-joining-as-CFO-and-Dr-Andy-Hu-as-CBO.html

GLOBENEWSWIRE
30 Apr 2025

https://www.globenewswire.com/news-release/2025/04/09/3058265/0/en/Augustine-Therapeutics-appoints-Industry-Veteran-Pascale-Witz-as-Chair-of-its-Board-of-Directors.html

GLOBENEWSWIRE
09 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty